Coordinator: Luis Montuenga/ Co-coordinator: Luis Paz Ares
The respiratory tract tumour programme sets out to provide a response to some of the key questions regarding tumours originating in the lungs, head and neck.
Lung cancer is the most commonly diagnosed type of cancer, with 1.82 million new cases a year all over the world. This type of cancer also has a high mortality rate, mainly because this is diagnosed in an advanced stage and because current therapies are not sufficiently effective. Only 15% of lung cancer patients consequently survive over 5 years.
In spite of the promising progress made over the last few years in the early detection and introduction of new treatments based on the biological profile of lung cancer, there still needs to be more in-depth scientific knowledge of the mechanisms involved in the initiation, progression and metastasis of these tumours. This is a key objective to be able to design new diagnostic, prognostic and therapeutic strategies which can be transferred to routine clinical practice.
By a combination of clinical and translational research, and structured into 5 different research groups, this programme seeks to face up to the current challenges of treatment of respiratory tract tumours, placing special emphasis on precision medicine and on the development and clinical evolution of new therapeutic targets and immune therapy strategies.
|Main Researcher||Consortium Institution||Regions|
|Luis Montuenga||Centro de Investigación Médica Aplicada||Navarra|
|Luis Paz-Ares||Hospital Universitario 12 de Octubre||Madrid|
|Amancio Carnero||Hospital Virgen del Rocio||Andalucía|
|Carlos Camps||Hospital General Universitario de Valencia||Valencia|
|Juan Rodrigo Tapia||Hospital Universitario Central de Asturias||Asturias|